Hookipa Pharma’s (HOOK) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a report released on Friday, Marketbeat Ratings reports.

A number of other research firms also recently weighed in on HOOK. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $48.00 to $2.00 in a research report on Friday, December 20th. JMP Securities decreased their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st.

Hookipa Pharma Price Performance

NASDAQ:HOOK opened at $2.15 on Friday. Hookipa Pharma has a one year low of $1.75 and a one year high of $10.50. The company has a fifty day moving average price of $2.48 and a 200 day moving average price of $4.08. The stock has a market cap of $25.92 million, a P/E ratio of -0.58 and a beta of 0.71.

Institutional Trading of Hookipa Pharma

A number of large investors have recently bought and sold shares of the stock. Ikarian Capital LLC bought a new position in shares of Hookipa Pharma in the third quarter valued at approximately $228,000. Renaissance Technologies LLC raised its position in Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Hookipa Pharma by 12.3% in the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after purchasing an additional 108,844 shares in the last quarter. 63.88% of the stock is currently owned by institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.